Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis-lifestyle and consumer packaged
goods company inspiring and empowering the worldwide community to
live their very best life, today announced that its medical
cannabis division, Tilray Medical, has expanded its medical
cannabis offerings in the United Kingdom. Tilray Medical now offers
the broadest portfolio of cannabis flower in the UK market today,
including a differentiated range of high THC products, cultivated
at its EU-GMP-certified facility in Portugal.
Denise Faltischek, Tilray’s Chief Strategy
Officer, and Head of International Business, said, “The demand for
medical cannabis in the UK is growing rapidly. We are incredibly
proud to provide patients in the UK with high-quality, consistent
medical cannabis products they can rely on and are accessible to
them.”
Tilray Medical now offers an extensive selection
of medical cannabis products including a market leading portfolio
of cannabis flowers with THC potencies that span from 10% to 25%
and offer a range of different ratios1. Tilray Medical’s portfolio
in the UK is underpinned by a breadth of cultivars, each with a
unique profile of cannabinoids and terpenes, that have been
selected to ensure patients can receive both the highest product
quality as well as consistency when it comes to supply of their
medicinal cannabis products. By offering such a broad range of
cannabis flower products in the UK, Tilray Medical hopes to expand
the range of treatment options available to patients and ensure
prescribers and patients are provided with a safe and reliable
choice as they embark on their medical cannabis journey.
In the UK, patients may obtain prescriptions for
medical cannabis through their specialist doctor. Tilray Medical
supplies the UK and the rest of our international business with
EU-GMP certified medical cannabis from our state-of-the-art
facilities in Portugal, providing patients with safe and reliable
access to high-quality medical cannabis.
For more information about Tilray medical
cannabis and the above cultivars available in the UK, visit:
https://tilraymedical.co.uk/
About Tilray
Medical Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew
from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first EU-GMP-certified cannabis production facilities in Europe,
first in Portugal and later in Germany. Today, Tilray Medical is
one of the biggest suppliers of medical cannabis brands to
patients, physicians, hospitals, pharmacies, researchers, and
governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Canada, Tilray Medical Australia, Tilray Medical
Australia-New Zealand, Tilray Medical Europe
About Tilray BrandsTilray
Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people's lives for the better – one
person at a time. Tilray Brands delivers on this mission by
inspiring and empowering the worldwide community to live their very
best life and providing access to products that meet the needs of
their mind, body, and soul while invoking wellbeing. Patients and
consumers trust Tilray Brands to deliver a cultivated experience
and health and wellbeing through high-quality, differentiated
brands and innovative products. A pioneer in cannabis research,
cultivation, and distribution, Tilray’s unprecedented production
platform supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and craft
beverages.
For more information on how we open a world of
wellbeing, visit www.Tilray.com and follow @Tilray on Instagram and
Twitter.
Forward-Looking
StatementsCertain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical. Many factors could cause
actual results, performance, or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities laws.
For further information: Berrin Noorata Media,
Tilray Global: news@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.com
________________________________1 Actual
cannabinoid content may vary. Tilray products are manufactured
under EU-GMP standards and adhere to product specifications in line
with European pharmaceutical standards.
Tilray Brands (TSX:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (TSX:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024